Addendum
Dostarlimab (endometrial cancer) - Addendum to commission A21-84
Report documents
-
Addendum
Dostarlimab (endometrial cancer) - Addendum to commission A21-84
Dossier assessment
Indication:
Adult patients with mismatch repair deficient/microsatellite instability-high recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen
Result of dossier assessment:
Unchanged after addendum: Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2021-12-02 A G-BA decision was published.
Project details
- Project no.
- A21-139
- Commission
- Commission awarded on 26.10.2021 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Dostarlimab (endometrial cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed